PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
New England Journal of Medicine2018Vol. 379(4), pp. 341–351
Citations Over TimeTop 1% of 2018 papers
Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, Leonel F. Hernandez‐Aya, Annette M. Lim, Anne Lynn S. Chang, Guilherme Rabinowits, Alesha Thai, Lara Dunn, Brett Hughes, Nikhil I. Khushalani, Badri Modi, Dirk Schadendorf, Bo Gao, Frank Seebach, Siyu Li, Jingjin Li, Melissa Mathias, Jocelyn Booth, Kosalai Kal Mohan, Elizabeth Stankevich, Hani M. Babiker, Irene Braña, Marta Gil-Martín, Jade Homsi, Melissa L. Johnson, Víctor Moreno, Jiaxin Niu, Taofeek K. Owonikoko, Kyriakos P. Papadopoulos, George D. Yancopoulos, Israel Lowy, Matthew G. Fury
Abstract
Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT02383212 and NCT02760498 .).
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)